Results 131 to 140 of about 31,874 (263)

Liver Fibrosis: Molecular Pathogenesis and Therapeutic Interventions

MedComm, Volume 7, Issue 5, May 2026.
We systematically summarized the etiologies, diagnostic approaches, and pathogenic mechanisms of liver fibrosis. Also, the therapeutic interventions for liver fibrosis were systematically classified into two main categories: etiological treatment and mechanism‐based antifibrotic therapies.
Jiaorong Qu, Wenqing Qin, Minghang Dong, Zhi Ma, Si Li, Runping Liu, Ranyun Chen, Changmeng Li, Xiaojiaoyang Li   +8 more
wiley   +1 more source

Carrier screening in the reproductive setting—Are there medical implications for the heterozygote?—A guide for clinicians

Pregnancy, Volume 2, Issue 3, May 2026.
Abstract Carrier screening for genetic conditions performed preconception or during pregnancy allows identification of fetal risk for inherited autosomal recessive and X‐linked conditions. The goal is to identify at‐risk patients/couples and offer them reproductive options such as preimplantation genetic diagnosis, prenatal testing, or targeted newborn
Emily B. Rosenfeld, Nicole Kasatkin, Bi Liu Yu, Milen Velinov, Justin S. Brandt, Elena Ashkinadze   +5 more
wiley   +1 more source

Successful conservative management of a dog with postoperative bile peritonitis after cholecystectomy

Veterinary Record Case Reports, Volume 14, Issue 2, May 2026.
Summary An 11‐year‐old, female, spayed chihuahua was diagnosed with septic bile peritonitis secondary to gall bladder rupture. Surgical treatment consisted of cholecystectomy, placement of an abdominal drain and an oesophagostomy tube. The dog developed aspiration pneumonia alongside a recurrent bile peritonitis postoperatively.
Lydia Tan Yi Shean, Phil H. Franklin
wiley   +1 more source

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 9, Page 1215-1235, May 2026.
Peroxisome proliferator‐activated receptor (PPAR) agonists have emerged as important second‐line treatments in primary biliary cholangitis, with profiles influenced by different selectivity for α‐, δ‐ and γ‐isoforms. PPAR‐α and PPAR‐δ agonism improve cholestasis, with inflammation reduced via all isoforms. PPAR‐δ agonism also reduces pruritus.
Jörn M. Schattenberg, Jesus M. Banales, Gideon Hirschfield, Palak Trivedi, Edward E. Cable, Charles A. McWherter, Andrew N. Billin, Daria B. Crittenden, Grant Budas   +8 more
wiley   +1 more source

Cholangiolocellular Component Predicts a Biologically Distinct Subgroup of Mass‐Forming Intrahepatic Cholangiocarcinoma

Cancer Science, Volume 117, Issue 5, Page 1510-1523, May 2026.
We identified two distinct molecular subgroups of mass‐forming intrahepatic cholangiocarcinoma (MF‐iCCA) based on the presence of a histological cholangiolocellular carcinoma (CLC) component. The CLC‐related molecular subgroup showed better prognosis and highly angiogenic features, as confirmed by both genetic analysis and morphological observation ...
Naoto Kubota, Ken Yamazaki, Yasuhito Arai, Minoru Esaki, Nobuyoshi Hiraoka, Hirofumi Shirakawa, Moriaki Tomikawa, Tatsuhiro Shibata, Michiie Sakamoto, Hidenori Ojima   +9 more
wiley   +1 more source

Early‐Onset Digestive System Cancers: Risk Factors and Clinicopathological and Molecular Features Across Organ Sites

Cancer Science, Volume 117, Issue 5, Page 1223-1234, May 2026.
Shared risk factors, clinical features, and tumor characteristics across multiple early‐onset cancer types are shown in this Graphical Abstract. Integrative approaches combining molecular pathology, oncology, and population sciences offer opportunities to clarify underlying mechanisms and help us develop preventive strategies for early‐onset cancers ...
Nobuhiro Nakazawa, Satoko Ugai, Atsushi Kondo, Kosuke Matsuda, Shu Kato, Genki Usui, Shiori Tanaka, Hwa‐Young Lee, Xinyuan Zhang, Hideo Miyagawa, Mai Chan Lau, Hiroshi Saeki, Yukihide Kanemitsu, Andrew T. Chan, Shuji Ogino, Minkyo Song, Juha P. Väyrynen, Tomotaka Ugai   +17 more
wiley   +1 more source

Intrahepatic Bile Duct Epithelium [PDF]

, 2020
openaire   +1 more source

Intrahepatic bile duct strictures in a liver allograft recipient mimicking recurrent primary sclerosing cholangitis - Follow-up of a case report [PDF]

, 1991
Demetris, AJ, Gordon, R, Hartman, GG, Lerut, J, Starzl, TE   +4 more
core   +1 more source

Prognostication of Liver Disease Patients via the WFUMB ‘Rule‐of‐4’ Algorithm Using SSI‐2D‐SWE‐Based Liver Stiffness Measurement

Liver International, Volume 46, Issue 5, May 2026.
ABSTRACT Background The World Federation for Ultrasound in Medicine and Biology (WFUMB) guidance update 2024 proposed a ‘rule‐of‐4’ using ARFI liver stiffness measurement (LSM) to stratify the risk of decompensation events. This rule identifies advanced chronic liver disease (ACLD) at a threshold of ≥ 13 kPa and indicates a high probability of ...
Christian Sebesta, Georg Kramer, Nina Dominik, Benedikt S. Hofer, Lorenz Balcar, Paul Thöne, Mathias Jachs, Lukas Hartl, Benedikt Simbrunner, Till Schöchtner, Friedrich Haimberger, Nicolas Balutsch, Albert F. Stättermayer, Michael Trauner, Mattias Mandorfer, Thomas Reiberger, David J. M. Bauer   +16 more
wiley   +1 more source

Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVE

Liver International, Volume 46, Issue 5, May 2026.
ABSTRACT Background & Aims Baseline alkaline phosphatase (ALP) levels can influence the likelihood of achieving dichotomous biochemical response criteria in primary biliary cholangitis (PBC). This concept was explored using Week 52 data from the phase III ELATIVE trial (NCT04526665), which assessed elafibranor, a peroxisome proliferator‐activated ...
Cynthia Levy, Christopher L. Bowlus, Eric Lawitz, Nuno Antunes, Benjamin Miller, Jianfen Shu, Claudia O. Zein, Kris V. Kowdley   +7 more
wiley   +1 more source